The Latest Breaking News from AstraZeneca

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

Chancellor hopes to cut state aid for Speke vaccine plant to £40m. But pro-growth Treasury must not let project slip overseas

Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant

Editorial: The latest High Pay Centre report confirms the persistent and damaging culture of entitlement at the top of business

AstraZeneca’s Pascal Soriot and Rolls Royce’s Tufan Erginbilgic were among the highest-paid FTSE 100 CEOs, but what they make still trails behind the average pay of S&P 500 CEOs.

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.

These five companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks included.